Arrowhead Pharmaceuticals is moving higher as investors react to newly highlighted long-term efficacy and safety results for plozasiran (ARO-APOC3), including two-year open-label extension outcomes across hypertriglyceridemia populations. The company’s update emphasized large, durable triglyceride reductions and a continued development path aimed at regulatory submissions for severe hypertriglyceridemia in mid-2026. (ir.arrowheadpharma.com)

Plozasiran is a key value driver in Arrowhead’s cardiometabolic franchise, and long-duration datasets can shift investor expectations about real-world durability, safety, and commercial positioning. The company highlighted that severe hypertriglyceridemia patients achieved an 83% median triglyceride reduction in the two-year extension, and it framed the results as supportive of broader use across a spectrum of hypertriglyceridemia. (ir.arrowheadpharma.com)

Near-term focus is on execution toward planned regulatory submissions for plozasiran in severe hypertriglyceridemia in mid-2026, alongside additional 2026 clinical and commercial catalysts that management has discussed in recent investor-conference updates. Any incremental clarity on timelines, label scope, or payer/commercial launch metrics can materially affect sentiment given Arrowhead’s transition from pipeline-only to commercial-stage. (ir.arrowheadpharma.com)